Asset Planning Inc Buys New Shares in Edwards Lifesciences Co. (NYSE:EW)

Asset Planning Inc bought a new stake in shares of Edwards Lifesciences Co. (NYSE:EW) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 26,922 shares of the medical research company’s stock, valued at approximately $1,993,000. Edwards Lifesciences accounts for approximately 1.5% of Asset Planning Inc’s portfolio, making the stock its 13th largest holding.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Banque Pictet & Cie SA increased its stake in Edwards Lifesciences by 106.2% during the 4th quarter. Banque Pictet & Cie SA now owns 156,968 shares of the medical research company’s stock valued at $11,620,000 after purchasing an additional 80,851 shares in the last quarter. V Square Quantitative Management LLC grew its stake in shares of Edwards Lifesciences by 2.3% in the 4th quarter. V Square Quantitative Management LLC now owns 15,374 shares of the medical research company’s stock worth $1,138,000 after acquiring an additional 348 shares in the last quarter. Bogart Wealth LLC grew its stake in shares of Edwards Lifesciences by 38.2% in the 4th quarter. Bogart Wealth LLC now owns 92,768 shares of the medical research company’s stock worth $6,868,000 after acquiring an additional 25,657 shares in the last quarter. Asset Management One Co. Ltd. grew its stake in shares of Edwards Lifesciences by 1.0% in the 4th quarter. Asset Management One Co. Ltd. now owns 241,818 shares of the medical research company’s stock worth $18,294,000 after acquiring an additional 2,426 shares in the last quarter. Finally, Avestar Capital LLC bought a new stake in shares of Edwards Lifesciences in the 4th quarter worth $203,000. Institutional investors own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

EW has been the subject of several recent analyst reports. Morgan Stanley upped their target price on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Wednesday. The Goldman Sachs Group increased their price target on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, December 5th. Robert W. Baird reduced their price target on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and increased their price target for the company from $82.00 to $90.00 in a research report on Monday, December 16th. Finally, Daiwa America lowered shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 30th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat.com, Edwards Lifesciences currently has an average rating of “Hold” and an average price target of $79.95.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 11,250 shares of the business’s stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $75.76, for a total transaction of $852,300.00. Following the completion of the sale, the chief financial officer now directly owns 30,561 shares in the company, valued at $2,315,301.36. The trade was a 26.91 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Daniel J. Lippis sold 500 shares of the business’s stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the sale, the vice president now owns 23,189 shares of the company’s stock, valued at approximately $1,594,475.64. This represents a 2.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 20,750 shares of company stock valued at $1,564,255 in the last quarter. 1.29% of the stock is owned by insiders.

Edwards Lifesciences Stock Up 0.2 %

Shares of Edwards Lifesciences stock opened at $75.96 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12. The stock has a market capitalization of $44.80 billion, a price-to-earnings ratio of 10.96, a P/E/G ratio of 3.64 and a beta of 1.10. The company’s 50 day moving average price is $72.51 and its 200-day moving average price is $69.36.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. Equities research analysts forecast that Edwards Lifesciences Co. will post 2.56 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.